The GIANT trial (EA2186) is the first randomized clinical trial to focus on vulnerable older adults with treatment-naïve metastatic pancreatic cancer who are not candidates for standard therapy
The purpose of the Symposium is to introduce young investigators to ECOG-ACRIN and provide them with a forum to present their research in a formal manner and obtain feedback
October accrual is on pace to be the highest month on record. Since July 1, TMIST has enrolled more patients than all other National Cancer Institute clinical trials combined. An unheard-of number (nearly 20%) are Black and African American women. Drs. Etta Pisano and Mitch Schnall provide the latest status of the trial and discuss its continuing relevance
This phase II study, led by Dr. Bonnie Ky, aims to generate the necessary data to inform a phase III randomized controlled trial with the potential to make a significant public health impact
This is the only study that is currently designed to test the ability to improve long-term outcomes by refining early-setting triple-negative breast cancer chemotherapy without exposing ALL patients to more toxicity preoperatively